Abstract
Get full access to this article
View all access options for this article.
References
1.
Davies A
,
Prentice W
. Diminished effect of transdermal fentanyl in the terminal phase?
Palliat Med
1997 ; 11 : 168 -169 .
2.
Cherny N
,
Ripamonti C
,
Pereira J
, et al. Strategies to manage the adverse effects of oral morphine: an evidencebased report . J Clin Oncol
2001 ; 19 : 2542 -2554 .
3.
McNamara P.
Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care . Palliat Med
2002 ; 16 : 425 -434 .
4.
Radbruch L
,
Sabatowski R
,
Petzke F
,
Brunsch-Radbruch A
,
Grond S
,
Lehmann K
. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients . Palliat Med
2001 ; 15 : 309 -321 .
5.
McLoughlin R.
Transdermal fentanyl and respiratory depression . Palliat Med
1997 ; 11 : 419 -419 .
6.
Feely J
,
Moriarty S
,
O'Connor P
. Stimulating reporting of adverse drug reactions by using a fee . BMJ
1990 ; 300 : 22 -23 .